Therapy of endocrine disease: The challenges in managing giant prolactinomas

European Journal of Endocrinology

Volumn 170, Issue 6, 2014, Pages

  Maiter, Dominique ^a   Delgrange, Etienne ^b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; OCTREOTIDE; PASIREOTIDE; PENTETREOTIDE IN 111; PERGOLIDE; PROLACTIN; TEMOZOLOMIDE;

CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CRANIAL NERVE PARALYSIS; DIAGNOSTIC ACCURACY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; EXOPHTHALMOS; HUMAN; HYDROCEPHALUS; HYPERPROLACTINEMIA; IMMUNORADIOMETRIC ASSAY; NEUROSURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; REVIEW; SEX DIFFERENCE; SEX RATIO; TEMPORAL LOBE EPILEPSY; TRANSSPHENOIDAL HYPOPHYSECTOMY; TUMOR VOLUME;

DIAGNOSTIC IMAGING; FEMALE; HUMANS; MALE; PITUITARY NEOPLASMS; PROLACTINOMA; TUMOR BURDEN;

EID: 84902589470     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0013     Document Type: Review

References (128)

1. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA & Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. Journal of Clinical Endocrinology and Metabolism 2006 91 4769-4775. (doi:10.1210/jc.2006-1668)
2. Fernandez A, Karavitaki N & Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clinical Endocrinology 2010 72 377-382. (doi:10.1111/j.1365-2265.2009.03667.x)
3. Raappana A, Koivukangas J, Ebeling T & Pirilä T. Incidence of pituitary adenomas in Northern Finland in 1992-2007. Journal of Clinical Endocrinology and Metabolism 2010 95 4268-4275. (doi:10.1210/jc.2010-0537)
4. Gillam MP, Molitch ME, Lombardi G & Colao A. Advances in the treatment of prolactinomas. Endocrine Reviews 2006 27 485-534. (doi:10.1210/er.2005-9998)
5. Delgrange E, Trouillas J, Maiter D, Donckier J & Tourniaire J. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. Journal of Clinical Endocrinology and Metabolism 1997 82 2102-2107. (doi:10.1210/jcem.82.7.4088)
6. Moraes AB, Silva CM, Vieira Neto L & Gadelha MR. Giant prolactinomas: the therapeutic approach. Clinical Endocrinology 2013 79 447-456. (doi:10.1111/cen.12242)
7. Shrivastava RK, Arginteanu MS, King WA & Post KD. Giant prolactinomas: clinical management and long-term follow-up. Journal of Neurosurgery 2002 97 299-306. (doi:10.3171/jns.2002.97.2.0299)
8. Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA & Colosimo C. Giant prolactinomas in men: efficacy of cabergoline treatment. Clinical Endocrinology 2003 58 662-670. (doi:10.1046/j.1365-2265.2003.01770.x)
9. Jefferson G. Extrasellar extensions of pituitary adenomas. Proceedings of the Royal Society of Medicine 1940 33 433-458.
10. Symon L, Jakubowski J & Kendall B. Surgical treatment of giant pituitary adenomas. Journal of Neurology, Neurosurgery, and Psychiatry 1979 42 973-982. (doi:10.1136/jnnp.42.11.973)
11. Davis JRE, Sheppard MC & Heath DA. Giant invasive prolactinoma: a case report and review of nine further cases. Quarterly Journal of Medicine 1990 275 227-238. (Pubitemid 20121042)
12. Murphy FY, Vesely DL, Jordan RM, Flanigan S & Kohler PO. Giant invasive prolactinomas. American Journal of Medicine 1987 83 995-1002. Erratum in: American Journal of Medicine 1987 83 A11. (doi:10.1016/0002-9343(87)90668-1)
13. Grebe SK, Delahunt JW & Feek CM. Treatment of extensively invasive (giant) prolactinomas with bromocriptine. New Zealand Medical Journal 1992 105 129-131.
14. Majós C, Coll S, Aguilera C, Acebes JJ & Pons LC. Imaging of giant pituitary adenomas. Neuroradiology 1998 40 651-655. (doi:10.1007/ s002340050657)
15. Delgrange E, Raverot G, Bex M, Burman P, Decoudier B, Devuyst F, Feldt-Rasmussen U, Andersen M & Maiter D. Giant prolactinomas in women. European Journal of Endocrinology 2014 170 31-38. (doi:10.1530/EJE-13-0503)
16. Symon L. Management of giant intracranial aneurysms. Clinical Neurosurgery 1990 36 21-47.
17. Yang MY, Shen CC & Ho WL. Treatments of multi-invasive giant prolactinoma. Journal of Clinical Neuroscience 2004 11 70-75. (doi:10.1016/j.jocn.2002.11.002)
18. Mohr G, Hardy J, Comtois R & Beauregard H. Surgical management of giant pituitary adenomas. Canadian Journal of Neurological Sciences 1990 17 62-66. (Pubitemid 20101027)
19. St-Jean E, Blain F & Comtois R. High prolactin levels may bemissed by immunoradiometric assay in patients with macroprolactinomas. Clinical Endocrinology 1996 44 305-309. (doi:10.1046/j.1365-2265.1996.663486.x)
20. Cho EH, Lee SA, Chung JY, Koh EH, Cho YH, Kim JH, Kim CJ & Kim MS. Efficacy and safety of cabergoline as first line treatment for invasive giant prolactinoma. Journal of Korean Medical Science 2009 24 874-878. (doi:10.3346/jkms.2009.24.5.874)
21. Lundberg PO, Osterman PO & Wide L. Serum prolactin in patients with hypothalamus and pituitary disorders. Journal of Neurosurgery 1981 55 194-199. (doi:10.3171/jns.1981.55.2.0194)
22. Saeki N, Nakamura M, Sunami K & Yamaura A. Surgical indication after bromocriptine therapy on giant prolactinomas: effects and limitations of the medical treatment. Endocrine Journal 1998 45 529-537. (doi:10.1507/endocrj.45. 529)
23. Acharya SV, Gopal RA, Menon PS, Bandgar TR & Shah NS. Giant prolactinoma and effectiveness of medical management. Endocrine Practice 2010 16 42-46. (doi:10.4158/EP09221.OR)
24. Mascarell S & Sarne DH. Clinical presentation and response to therapy in patients with massive prolactin hypersecretion. Pituitary 2007 10 95-101. (doi:10.1007/s11102-007-0009-y)
25. Shimon I, Benbassat C & Hadani M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. European Journal of Endocrinology 2007 156 225-231. (doi:10.1530/EJE-06-0646)
26. Wu ZB, Yu CJ, Su ZP, Zhuge QC, Wu JS & Zheng WM. Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up. Journal of Neurosurgery 2006 104 54-61. (doi:10.3171/jns.2006.104.1.54)
27. Raverot G, Wierinckx A, Dantony E, Auger C, Chapas G, Villeneuve L, Brue T, Figarella-Branger D, Roy P, Jouanneau E et al. Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. Journal of Clinical Endocrinology and Metabolism 2010 95 1708-1716. (doi:10.1210/jc.2009-1191)
28. Schaller B. Gender-related differences in prolactinomas. A clinicopathological study. Neuroendocrinology Letters 2005 26 152-159. Erratum in: Neuroendocrinology Letters 2005 26 628. (Pubitemid 40674219)
29. Frieze TW, Mong DP & Koops MK. "Hook effect", in prolactinomas: case report and review of literature. Endocrine Practice 2002 8 296-303. (doi:10.4158/EP.8.4.296)
30. Schöfl C, Schöfl-Siegert B, Karstens JH, Bremer M, Lenarz T, Cuarezma JS, Samii M, von zur Mühlen A & Brabant G. Falsely low serum prolactin in two cases of invasive macroprolactinoma. Pituitary 2002 5 261-265. (doi:10.1023/A:1025334001748)
31. Berwaerts J, Verhelst J, Abs R, Appel B & Mahler C. A giant prolactinoma presenting with unilateral exophthalmos: effect of cabergoline and review of the literature. Journal of Endocrinological Investigation 2000 23 393-398. (doi:10.1007/BF03343743)
32. Siegel RD & Lee SL. Pneumocephalus and cerebrospinal fluid rhinorrhea after bromocriptine therapy of an invasive prolactinoma: a case report and review of the literature. Endocrinologist 1996 6 148-152. (doi:10.1097/00019616- 199603000-00012)
33. Cole DR, Lees PD & Armitage M. A good wife, but never a mother. Journal of the Royal Society of Medicine 1995 88 176P-178P.
34. Minniti G, Jaffrain-Rea ML, Santoro A, Esposito V, Ferrante L, Delfini R & Cantore G. Giant prolactinomas presenting as skull base tumors. Surgical Neurology 2002 57 99-104. (doi:10.1016/S0090-3019(01)00697-8)
35. Ahmed M & Al-Nozha O. Images in clinical medicine. Large prolactinoma. New England Journal of Medicine 2010 363 177. (doi:10.1056/ NEJMicm0906033)
36. Deepak D, Daousi C, Javadpour M & MacFarlane IA. Macroprolactinomas and epilepsy. Clinical Endocrinology 2007 66 503-507. (doi:10.1111/j.1365-2265. 2007.02759.x)
37. Brisman MH, Fetell MR & Post KD. Reversible dementia due to macroprolactinoma. Case report. Journal of Neurosurgery 1993 79 135-137. (doi:10.3171/jns.1993.79.1.0135)
38. Scarone P, Losa M, Mortini P & Giovanelli M. Obstructive hydrocephalus and intracranial hypertension caused by a giant macroprolactinoma. Prompt response to medical treatment. Journal of Neuro-Oncology 2006 76 51-54. (doi:10.1007/s11060-005-2319-0)
39. Alkatari S & Aljohani N. Obstructive hydrocephalus, fifth nerve and hypothalamus involvement: acute presentation of a giant prolactinoma. Clinical Medicine Insights. Case Reports 2012 5 115-118. (doi:10.4137/CCRep.S9675)
40. Iglesias P, Perez Macho L & Diez JJ. Resolution of macroprolactinoma-induced symptomatic hydrocephalus following cabergoline therapy. Age and Ageing 2004 33 410-412. (doi:10.1093/ageing/afh108)
41. Levy RA & Quint DJ. Giant pituitary adenoma with unusual orbital and skull base extension. American Journal of Roentgenology 1998 170 194-196. (doi:10.2214/ajr.170.1.9423631)
42. Barkan AL & Chandler WF. Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the "high-dose hook effect": case report. Neurosurgery 1998 42 913-915. (doi:10.1097/00006123-199804000-00126)
43. Zikel OM, Atkinson JLD & Hurley DL. Prolactinoma manifesting with symptomatic hydrocephalus. Mayo Clinic Proceedings 1999 74 475-477. (doi:10.1016/S0025-6196(11)65126-4)
44. Freda PU, Andreadis CI, Khandji AG, Khoury M, Bruce JN, Jacobs TP & Wardlaw SL. Long-term treatment of prolactin-secreting macroadenomas with pergolide. Journal of Clinical Endocrinology and Metabolism 2000 85 8-13. (doi:10.1210/jcem.85.1.6329)
45. Harzallah F, Harzallah L, Ben Brahim A, Mekaouer A & Slimane H. Macroadénome à prolactine révélé par une exophtalmie. Journal of Français d'Ophthalmolgie 2009 32 133.e1-133.e3. (doi:10.1016/j.jfo.2008.12.005)
46. Siddiqui A, Chew N & Miszkiel K. Unusual orbital invasion by a giant prolactinoma. British Journal of Radiology 2008 81 259-262. (doi:10.1259/bjr/ 98771490)
47. Chattopadhyay A, Bhansali A & Masoodi SR. Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men. Pituitary 2005 8 147-154. (doi:10.1007/s11102-005-5111-4)
48. Fleseriu M, Lee M, Pineyro MM, Skugor M, Reddy SK, Siraj ES & Hamrahian AH. Giant invasive pituitary prolactinoma with falsely low serum prolactin: the significance of 'hook effect'. Journal of Neuro-Oncology 2006 79 41-43. (doi:10.1007/s11060-005-9108-7)
49. Baldari S, Ferraù F, Alafaci C, Herberg A, Granata F, Militano V, Salpietro FM, Trimarchi F & Cannavò S. First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment. Pituitary 2012 15 (Suppl 1) S57-S60. (doi:10.1007/s11102-011-0373-5)
50. Grozinsky-Glasberg S & Shimon I. Unusual clinical presentations of giant prolactinomas. Pituitary 2011 14 340-344. (doi:10.1007/s11102-008-0160-0)
51. Lam G, Mehta V & Zada G. Spontaneous and medically induced cerebrospinal fluid leakage in the setting of pituitary adenomas: review of the literature. Neurosurgical Focus 2012 32 E2. (doi:10.3171/2012.4.FOCUS1268)
52. Cappabianca P, Lodrini S, Felisati G, Peca C, Cozzi R, Di Sarno A, Cavallo LM, Giombini S & Colao A. Cabergoline-induced CSF rhinorrhea in patients with macroprolactinoma. Report of three cases. Journal of Endocrinological Investigation 2001 24 183-187. (Pubitemid 32293641)
53. Inagawa H, Ishizawa K, Mitsuhashi T, Shimizu M, Adachi J, Nishikawa R, Matsutani M & Hirose T. Giant invasive pituitary adenoma extending into the sphenoid sinus and nasopharynx: report of a case with intraoperative cytologic diagnosis. Acta Cytologica 2005 49 452-456. (doi:10.1159/000326184)
54. Care RH, Sunkaraneni VS, Theaker J & Harries PG. Rapidly progressing giant invasive prolactinoma. Journal of Laryngology and Otology 2012 126 840-843. (doi:10.1017/S0022215112001296)
55. Sunil B, Reddy A, Bryant N, Young DW & Ashraf AP. Invasive giant prolactinoma presenting as a nasal polyp. Journal of Pediatrics 2013 162 435. (doi:10.1016/j.jpeds.2012.08.029)
56. Cackett P, Eunson G, Bath L & Mulvihill A. Proptosis as the presenting sign of giant prolactinoma in a prepubertal boy: successful resolution of hydrocephalus by use of medical therapy. Future Oncology 2012 8 1-6. (doi:10.2217/fon.12.149)
57. Mallea-Gil MS, Cristina C, Perez-Millan MI, Villafañe AM, Ballarino C, Stalldecker G & Becu-Villalobos D. Invasive giant prolactinoma with loss of therapeutic response to cabergoline: expression of angiogenic markers. Endocrine Pathology 2009 20 35-40. (doi:10.1007/s12022-009-9057-3)
58. Steinberg J, Cohen JE, Gomori JM, Fraifeld S, Moscovici S, Rosenthal G, Shoshan Y & Itshayek E. Superficial siderosis of the central nervous system due to chronic hemorrhage from a giant invasive prolactinoma. Journal of Clinical Neuroscience 2013 20 1032-1034. (doi:10.1016/j.jocn.2012.07.022)
59. Zaben MJ, Harrisson SE & Mathad NV. Giant prolactinoma causing cranio-cervical junction instability: a case report. British Journal of Neurosurgery 2011 25 754-756. (doi:10.3109/02688697.2010.544791)
60. Cunnah D & Besser M. Management of prolactinomas. Clinical Endocrinology 1991 34 231-235. (doi:10.1111/j.1365-2265.1991.tb00299.x)
61. Molitch ME, Thorner MO & Wilson C.Management of prolactinomas. Journal of Clinical Endocrinology and Metabolism 1997 82 996-1000. (doi:10.1210/jcem.82.4.3845)
62. Comtois R, Robert F & Hardy J. Immunoradiometric assays may miss high prolactin levels. Annals of Internal Medicine 1993 119 173. (doi:10.7326/0003-4819-119-2-199307150-00029)
63. Haller BL, Fuller KA, Brown WS, Koenig JW, Eveland BJ & Scott MG. Two automated prolactin immunoassays evaluated with demonstration of a high-dose "hook effect" in one. Clinical Chemistry 1992 38 437-438.
64. Delgrange E, de Hertogh R, Vankrieken L & Maiter D. Potential hook effect in prolactin assay in patients with giant prolactinoma. Clinical Endocrinology 1996 45 506-507. (doi:10.1046/j.1365-2265.1996.t01-1-00826.x)
65. Pakzaban P. Giant prolactinoma and hook effect. Neurology 2000 55 1415-1416. (doi:10.1212/WNL.55.9.1415)
66. Al Sifri SN & Raef H. The hook effect in prolactin immunoassays. Saudi Medical Journal 2004 25 656-659.
67. Yener S, Comlekci A, Arda N, Men S & Yesil S. Misdiagnosis due to the hook effect in prolactin assay. Medical Principles and Practice 2008 17 429-431. (doi:10.1159/000141512)
68. Cook RJ, Uttley D, Wilkins PR, Archer DJ & Bell BA. Prolactinomas in men masquerading as invasive skull base tumours. British Journal of Neurosurgery 1994 8 51-55. (doi:10.3109/02688699409002393)
69. van der Lely AJ, Knegt PP, Stefanko SZ, Tanghe HL, Singh R & Lamberts SW. Nasopharyngeal presentation of pituitary tumors. Differential diagnosis and treatment. Journal of Clinical Endocrinology and Metabolism 1992 74 811-813. (doi:10.1210/jc.74.4.811)
70. Pia HW, Grote E & Hildebrandt G. Giant pituitary adenomas. Neurosurgical Reviews 1985 8 207-220. (doi:10.1007/BF01815445)
71. Goel A, Nadkarni T, Muzumdar D, Desai K, Phalke U & Sharma P. Giant pituitary tumors: a study based on surgical treatment of 118 cases. Surgical Neurology 2004 61 436-445. (doi:10.1016/j.surneu.2003.08.036)
72. Perani D, Colombo N, Scotti G & Tonon C. Rapid size reduction of giant prolactinoma following medical treatment. Journal of Computer Assisted Tomography 1984 8 131-133. (doi:10.1097/00004728-198402000-00027)
73. Yu C, Wu Z & Gong J. Combined treatment of invasive giant prolactinomas. Pituitary 2005 8 61-65. (doi:10.1007/s11102-005-5087-0)
74. Orrego JJ, Chandler WF & Barkan AL. Pergolide as primary therapy for macroprolactinomas. Pituitary 2000 3 251-256. (doi:10.1023/A:1012836331506)
75. Delgrange E, Daems T, Verhelst J, Abs R & Maiter D. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. European Journal of Endocrinology 2009 160 747-752. (doi:10.1530/EJE-09-0012)
76. Yarman S, Kurtulmus N & Bilge A. Optimal effective doses of cabergoline and bromocriptine and valvular lesions in men with prolactinomas. Neuroendocrinology Letters 2012 33 340-346.
77. Bevan JS, Webster J, Burke CW & Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocrine Reviews 1992 13 220-240. (doi:10.1210/edrv-13-2-220)
78. Yang MS, Hong JW, Lee SK, Lee EJ & Kim SH. Clinical management and outcome of 36 invasive prolactinomas treated with dopamine agonist. Journal of Neuro-Oncology 2011 104 195-204. (doi:10.1007/s11060-010-0459-3)
79. Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA & Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 2011 96 273-288. (doi:10.1210/jc.2010- 1692)
80. Ciric I, Mikhael M, Stafford T, Lawson L & Garces R. Transsphenoidal microsurgery of pituitary macroadenomas with long-term follow-up results. Journal of Neurosurgery 1983 59 395-401. (doi:10.3171/jns.1983.59.3.0395)
81. Guidetti B, Fraioli B & Cantore GP. Results of surgical management of 319 pituitary adenomas. Acta Neurochirurgica 1987 85 117-124. (doi:10.1007/BF01456107)
82. Dhanwal DK & Sharma AK. Brain and optic herniations into sella after cabergoline therapy of giant prolactinoma. Pituitary 2011 14 384-387. (doi:10.1007/s11102-009-0179-x)
83. Raverot G, Jacob M, Jouanneau E, Delemer B, Vighetto A, Pugeat M & Borson-Chazot F. Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma. Clinical Endocrinology 2009 70 588-592. (doi:10.1111/j.1365-2265.2008.03364.x)
84. Zhang X, Zhang W, Fu LA, Cheng JX, Liu BL, Cao WD, Fei Z, Zhang JN, Liu WP & Zhen HN. Hemorrhagic pituitary macroadenoma: characteristics, endoscopic endonasal transsphenoidal surgery, and outcomes. Annals of Surgical Oncology 2011 18 246-252. (doi:10.1245/s10434-010-1243-5)
85. Navarro-Bonnet J, Martínez-Anda JJ, Balderrama-Soto A, Pérez-Reyes SP, Pérez-Neri I & Portocarrero-Ortiz L. Stroke associated with pituitary apoplexy in a giant prolactinoma: a case report. Clinical Neurology and Neurosurgery 2013 14 101-103. (doi:10.1016/j.clineuro. 2013.09.039)
86. Primeau V, Raftopoulos C & Maiter D. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. European Journal of Endocrinology 2012 166 779-786. (doi:10.1530/EJE-11-1000)
87. Vroonen L, Jaffrain-Rea ML, Petrossians P, Tamagno G, Chanson P, Vilar L, Borson-Chazot F, Naves LA, Brue T, Gatta B et al . Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. European Journal of Endocrinology 2012 167 651-662. (doi:10.1530/EJE-12-0236)
88. Hamilton DK, Vance ML, Boulos PT & Laws ER. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary 2005 8 53-60. (doi:10.1007/s11102- 005-5086-1)
89. Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, Bonneville JF, Assaker R, Auger C, Brue T et al . A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 year post-operative follow-up. Acta Neuropathologica 2013 126 123-135. (doi:10.1007/s00401-013-1084-y)
90. Syro LV, Ortiz LD, Scheithauer BW, Lloyd R, Lau Q, Gonzalez R, Uribe H, Cusimano M, Kovacs K & Horvath E. Treatment of pituitary neoplasms with temozolomide: a review. Cancer 2011 117 454-462. (doi:10.1002/cncr.25413)
91. McCormack AI, Wass JA & Grossman AB. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. European Journal of Clinical Investigation 2011 41 1133-1148. (doi:10.1111/j.1365-2362.2011.02520.x)
92. Raverot G, Castinetti F, Jouanneau E, Morange I, Figarella-Branger D, Dufour H, Trouillas J & Brue T. Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clinical Endocrinology 2012 76 769-775. (doi:10.1111/j.1365-2265.2012.04381.x)
93. Jouanneau E, Wierinckx A, Ducray F, Favrel V, Borson-Chazot F, Honnorat J, Trouillas J & Raverot G. New targeted therapies in pituitary carcinoma resistant to temozolomide. Pituitary 2012 15 37-43. (doi:10.1007/s11102-011- 0341-0)
94. Whitelaw BC, Dworakowska D, Thomas NW, Barazi S, Riordan-Eva P, King AP, Hampton T, Landau DB, Lipscomb D, Buchanan CR et al. Temozolomide in the management of dopamine agonist resistant prolactinomas. Clinical Endocrinology 2012 76 877-886. (doi:10.1111/j.1365-2265.2012.04373.x)
95. Christoforidis A, Tsakalides C, Anastasiou A, Pavlaki A & Dimitriadou M. Impressive shrinkage of a giant prolactinoma treated with cabergoline in a prepubescent girl. What now? Neuroendocrinology Letters 2013 34 275-277.
96. Loh TW, Chiu TL, Wu SW, Hung HY, Chen KP & Su CF. Combined treatment of invasive giant prolactinoma with surgical excision, low-dose gamma knife radiosurgery, and a dopamine agonist - report of two cases. Tzu Chi Medical Journal 2011 23 135-138. (doi:10.1016/j.tcmj.2011.08.003)
97. Saraiva J, Gomes L, Paiva S, Ruas L & Carvalheiro M. Giant macroprolactinoma and pregnancy. Arquivos Brasileiros de Endocrinologia e Metabologia 2013 57 558-561. (doi:10.1590/S0004-27302013000700010)
98. Scott RM & Hedley-Whyte ET. A nine-year-old girl with cold intolerance, visual-field defects, and a suprasellar tumor. New England Journal of Medicine 2002 347 1604-1611. (doi:10.1056/NEJMcpc020011)
99. Calle-Rodrigue RDP, Giannini C, Scheithauer BW, Lloyd RV, Wollan PC, Kovacs KT, Stefaneanu L, Ebright AB, Abboud CF & Davis DH. Prolactinomas in male and female patients: a comparative clinicopathologic study. Mayo Clinic Proceedings 1998 73 1046-1052. (doi:10.4065/73.11.1046)
100. Sano K. Problems in the treatment of children with brain tumors. Progress in Experimental Tumor Research 1987 30 1-9.
101. Mindermann T & Wilson CB. Pediatric pituitary adenomas. Neurosurgery 1995 36 259-268. (doi:10.1227/00006123-199502000-00004)
102. Jackman S & Diamond F. Pituitary adenomas in childhood and adolescence. Pediatric Endocrinology Reviews 2013 10 450-459.
103. Partington MD, Davis DH, Laws ER Jr & Scheithauer BW. Pituitary adenomas in childhood and adolescence. Results of transsphenoidal surgery. Journal of Neurosurgery 1994 80 209-216. (doi:10.3171/jns.1994.80.2.0209)
104. Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, Sarnacchiaro F, Facciolli G & Lombardi G. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. Journal of Clinical Endocrinology and Metabolism 1998 83 2777-2780. (doi:10.1210/jcem.83.8.5001)
105. Angyal EA, Lee HJ, Wolansky LJ, Koenigsberger MR, Nathanson D & Zimmer AE. Prolactinoma invasion of superior ophthalmic vein: CT and MR findings. Journal of Computer Assisted Tomography 1993 17 964-966. (doi:10.1097/00004728-199311000-00020)
106. Semple P, Fieggen G, Parkes J & Levitt N. Giant prolactinomas in adolescence: an uncommon cause of blindness. Child's Nervous System 2007 23 213-217. (doi:10.1007/s00381-006-0177-5)
107. Ross RJ, McEniery JM, Grossman A, Doniach I, Besser GM & Savage MO. Massive prolactinoma with galactorrhoea in a prepubertal boy. Postgraduate Medical Journal 1989 65 403-406. (doi:10.1136/pgmj.65.764.403)
108. Krassas GE, Pontikides N & Kaltsas T. Giant prolactinoma presented as unilateral exophthalmos in a prepubertal boy: response to cabergoline. Hormone Research 1999 52 45-48. (doi:10.1159/000023432)
109. Howell DL, Wasilewski K, Mazewski CM, Hudgins RJ & Meacham LR. The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma. Journal of Pediatric Hematology/Oncology 2005 27 326-329. (doi:10.1097/01.mph.0000168727.41896.d2)
110. Dinc C, Bikmaz K, Iplikcioglu AC, Kosdere S & Latifaci I. Cystic giant prolactinoma in childhood. Journal of Clinical Neuroscience 2008 15 76-79. (doi:10.1016/j.jocn.2006.09.010)
111. Jennings JE, Georgitsi M, Holdaway I, Daly AF, Tichomirowa M, Beckers A, Aaltonen LA, Karhu A & Cameron FJ. Aggressive pituitary adenomas occurring in young patients in a large Polynesian kindred with a germline R271W mutation in the AIP gene. European Journal of Endocrinology 2009 161 799-804. (doi:10.1530/EJE-09-0406)
112. Fraioli MF, Novegno F, Catena E, Fraioli C & Moschettoni L. Multidisciplinary treatment of giant invasive prolactinomas in paediatric age: long-term follow-up in two children. Child's Nervous System 2010 26 1233-1237. (doi:10.1007/s00381-010-1129-7)
113. Furtado SV, Saikiran NA, Ghosal N & Hegde AS. Giant, solid, invasive prolactinoma in a prepubescent boy with gynecomastia. Pediatric Neurology 2010 42 72-74. (doi:10.1016/j.pediatrneurol.2009.08.005)
114. Chaurasia PK, Singh D, Meher S, Saran RK & Singh H. Epistaxis as first clinical presentation in a child with giant prolactinoma: case report and review of literature. Journal of Pediatric Neurosciences 2011 6 134-137. (doi:10.4103/1817-1745.92840)
115. Cuny T, Pertuit M, Sahnoun-Fathallah M, Daly A, Occhi G, Odou MF, Tabarin A, Nunes ML, Delemer B, Rohmer V et al. Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don't forget MEN1 genetic analysis. European Journal of Endocrinology 2013 168 533-541. (doi:10.1530/EJE-12-0763)
116. Keil MF & Stratakis CA. Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics. Expert Review of Neurotherapeutics 2008 8 563-574. (doi:10.1586/14737175.8.4.563)
117. Beckers A, Rostomyan L & Daly AF. Overview of genetic testing in patients with pituitary adenomas. Annales d'Endocrinologie 2012 73 62-64. (doi:10.1016/j.ando.2012.03.028)
118. Dworakowska D & Grossman AB. The molecular pathogenesis of pituitary tumors: implications for clinical management. Minerva Endocrinologica 2012 37 157-172.
119. Madsen H, Borges TM, Knox AJ, Michaelis KA, Xu M, Lillehei KO, Wierman ME & Kleinschmidt-DeMasters BK. Giant pituitary adenomas: pathologic- radiographic correlations and lack of role for p53 and MIB-1 labeling. American Journal of Surgical Pathology 2011 35 1204-1213. (doi:10.1097/PAS. 0b013e31821e8c96)
120. Wierinckx A, Roche M, Raverot G, Legras-Lachuer C, Croze S, Nazaret N, Rey C, Auger C, Jouanneau E, Chanson P et al. Integrated genomic profiling identifies loss of chromosome 11p impacting transcriptomic activity in aggressive pituitary PRL tumors. Brain Pathology 2011 21 533-543. (doi:10.1111/j.1750-3639.2011.00476.x)
121. Cooper O, Mamelak A, Bannykh S, Carmichael J, Bonert V, Lim S, Cook-Wiens G & Ben-Shlomo A. Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors. Endocrine 2014 In Press. (doi:10.1007/S12020-013- 0093-x)
122. Fukuoka H, Cooper O, Mizutani J, Tong Y, Ren SG, Bannykh S & Melmed S. HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. Molecular Endocrinology 2011 25 92-103. (doi:10.1210/me.2010-0353)
123. Jaquet P, Ouafik L, Saveanu A, Gunz G, Fina F, Dufour H, Culler MD, Moreau JP & Enjalbert A. Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. Journal of Clinical Endocrinology and Metabolism 1999 84 3268-3276. (doi:10.1210/jcem.84.9.5962)
124. Acosta-Gómez MJ, Muros MA, Llamas-Elvira JM, Ramírez A, Ortega S, Sabatel G, Ramos C & de la Riva-Aguilar A. The role of somatostatin receptor scintigraphy in patients with pituitary adenoma or postsurgical recurrent tumours. British Journal of Radiology 2005 78 110-115. (doi:10.1259/bjr/51245688)
125. Fusco A, Lugli F, Sacco E, Tilaro L, Bianchi A, Angelini F, Tofani A, Barini A, Lauriola L, Maira G et al. Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma. Pituitary 2011 14 351-357. (doi:10.1007/s11102-008-0162-y)
126. Hofland LJ, van der Hoek J, van Koetsveld P, de Herder WW, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, Feelders R, van der Lely AJ et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. Journal of Clinical Endocrinology and Metabolism 2004 89 1577-1585. (doi:10.1210/jc.2003- 031344)
127. Chinezu L, Vasiljevic A, Jouanneau E, François P, Borda A, Trouillas J & Raverot G. Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies. Human Pathology 2014 45 71-77. (doi:10.1016/j.humpath.2013.08.007)
128. Petakov MS, Damjanović SS, Nikolić-Durović MM, Dragojlović ZL, Obradović S, Gligorović S, Simić MZ & Popović VP. Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect. Journal of Endocrinological Investigation 1998 21 184-188. (Pubitemid 28223066)